Advanced

Tumour therapy with radionuclides: assessment of progress and problems

Carlsson, J; Aronsson, EF; Hietala, SA; Stigbrand, T and Tennvall, Jan LU (2003) In Radiotherapy and Oncology 66(2). p.107-111
Abstract
Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular... (More)
Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular processing of different types of targeting agents increases. There is also improved understanding of the factors of importance for the choice of appropriate radionuclides with respect to their decay properties and the therapeutic applications. Furthermore, new methods to modify the uptake of radionuclides in tumour cells and normal tissues are emerging. However, we still need improvements regarding dosimetry and treatment planning as well as an increased knowledge about the tolerance doses for normal tissues and the radiobiological effects on tumour cells. This is especially important in targeted radionuclide therapy where the dose rates often are lower than 1 Gy/h. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
tumour therapy, radionuclide therapy, effects, radiation, metastasis, disseminated tumour cells, low dose rate, review
in
Radiotherapy and Oncology
volume
66
issue
2
pages
107 - 111
publisher
Elsevier
external identifiers
  • wos:000183860000001
  • pmid:12648782
  • scopus:0037295293
ISSN
1879-0887
DOI
10.1016/S0167-8140(02)00374-2
language
English
LU publication?
yes
id
9d6ba30c-9979-42f3-881b-f93e2822cfd5 (old id 306962)
date added to LUP
2007-08-27 15:47:43
date last changed
2018-01-07 06:06:41
@article{9d6ba30c-9979-42f3-881b-f93e2822cfd5,
  abstract     = {Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular processing of different types of targeting agents increases. There is also improved understanding of the factors of importance for the choice of appropriate radionuclides with respect to their decay properties and the therapeutic applications. Furthermore, new methods to modify the uptake of radionuclides in tumour cells and normal tissues are emerging. However, we still need improvements regarding dosimetry and treatment planning as well as an increased knowledge about the tolerance doses for normal tissues and the radiobiological effects on tumour cells. This is especially important in targeted radionuclide therapy where the dose rates often are lower than 1 Gy/h. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.},
  author       = {Carlsson, J and Aronsson, EF and Hietala, SA and Stigbrand, T and Tennvall, Jan},
  issn         = {1879-0887},
  keyword      = {tumour therapy,radionuclide therapy,effects,radiation,metastasis,disseminated tumour cells,low dose rate,review},
  language     = {eng},
  number       = {2},
  pages        = {107--111},
  publisher    = {Elsevier},
  series       = {Radiotherapy and Oncology},
  title        = {Tumour therapy with radionuclides: assessment of progress and problems},
  url          = {http://dx.doi.org/10.1016/S0167-8140(02)00374-2},
  volume       = {66},
  year         = {2003},
}